NO20044964L - Flytende preparat som omfatter camptothecinderivat og farmasoytisk preparat som kan fremstilles ved a lyofilisere preparatet - Google Patents

Flytende preparat som omfatter camptothecinderivat og farmasoytisk preparat som kan fremstilles ved a lyofilisere preparatet

Info

Publication number
NO20044964L
NO20044964L NO20044964A NO20044964A NO20044964L NO 20044964 L NO20044964 L NO 20044964L NO 20044964 A NO20044964 A NO 20044964A NO 20044964 A NO20044964 A NO 20044964A NO 20044964 L NO20044964 L NO 20044964L
Authority
NO
Norway
Prior art keywords
prepared
pharmaceutical composition
preparation
camptothecin derivative
lyophilizing
Prior art date
Application number
NO20044964A
Other languages
English (en)
Inventor
Takahiro Lto
Shinji Narisawa
Original Assignee
Tanabe Seiyaku Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tanabe Seiyaku Co filed Critical Tanabe Seiyaku Co
Publication of NO20044964L publication Critical patent/NO20044964L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Foreliggende oppfinnelsen vedrører et stabilt flytende preparat som omfatter et camptothecinderivat som er fremstilt ved å binde sammen en forbindelse med formel [I] eller et farmasøytisk akseptabelt salt derav, som er justert til pH 5-8, eller et stabilt farmasøytisk preparat som er fremstilt ved å lyofilisere nevnte fiytende preparat. Foreliggende oppfinnelsen vedrører et stabilt flytende preparat som omfatter et camptothecinderivat som er fremstilt ved å binde sammen en forbindelse med formel [I], X' ¿Alk-0- der r' er en substituert eller ikke- subsitituert lavere alkylgmppe, X' er en gmppe med formel -NHR2 (R2 er et hydrogenatom eller en lavere alkylgmppe) eller en hydroksygruppe, og Alk er en rettkjedet eller forgrenet alkylengmppe som eventuelt er avbmtt av et oksygenatom, og et polysakkarid som har karboksylgrupper, via en aminosyre eller et peptid, eller et farmasøytisk akseptabelt salt derav, som er Justert til pH-S-8, eller et stabilt farmasøytisk preparat som er fiemstilt ved & lyofilisere nevnte flytende preparat.
NO20044964A 2002-04-16 2004-11-15 Flytende preparat som omfatter camptothecinderivat og farmasoytisk preparat som kan fremstilles ved a lyofilisere preparatet NO20044964L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2002112864 2002-04-16
PCT/JP2003/004745 WO2003086471A2 (en) 2002-04-16 2003-04-15 Lyophilized and liquid preparations comprising a polysaccharide derivative of camptothecin

Publications (1)

Publication Number Publication Date
NO20044964L true NO20044964L (no) 2004-11-15

Family

ID=29243336

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20044964A NO20044964L (no) 2002-04-16 2004-11-15 Flytende preparat som omfatter camptothecinderivat og farmasoytisk preparat som kan fremstilles ved a lyofilisere preparatet

Country Status (21)

Country Link
US (1) US20050215485A1 (no)
EP (1) EP1501549A2 (no)
JP (1) JP3927954B2 (no)
KR (1) KR100700963B1 (no)
CN (1) CN100544769C (no)
AR (1) AR039272A1 (no)
AU (1) AU2003223120B2 (no)
BR (1) BR0309283A (no)
CA (1) CA2480425A1 (no)
HR (1) HRP20040894A2 (no)
ME (1) MEP31308A (no)
MX (1) MXPA04010178A (no)
MY (1) MY136696A (no)
NO (1) NO20044964L (no)
PL (1) PL371677A1 (no)
RS (1) RS91204A (no)
RU (1) RU2315623C2 (no)
TW (1) TW200306314A (no)
UA (1) UA77295C2 (no)
WO (1) WO2003086471A2 (no)
ZA (1) ZA200408008B (no)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602005024923D1 (de) * 2004-02-13 2011-01-05 Yakult Honsha Kk Wässrige lösung mit einem camptothecin
CN1946421B (zh) 2004-04-27 2013-07-17 威尔斯达特生物制剂公司 使用病毒和喜树碱进行的癌症治疗
RU2435586C2 (ru) 2005-07-14 2011-12-10 Веллстат Байолоджикс Корпорейшн Лечение рака с применением вирусов, фторпиримидинов и камптотецинов
JP2007260275A (ja) * 2006-03-29 2007-10-11 Transcutaneous Technologies Inc イオントフォレーシス装置及びイオントフォレーシス投与用組成物
WO2010151544A1 (en) 2009-06-22 2010-12-29 Wyeth Llc Immunogenic compositions of staphylococcus aureus antigens
JP2012530785A (ja) 2009-06-22 2012-12-06 ワイス・エルエルシー 組成物および黄色ブドウ球菌（Ｓｔａｐｈｙｌｏｃｏｃｃｕｓａｕｒｅｕｓ）血清型５および８莢膜多糖コンジュゲート免疫原性組成物を調製するための方法
CN102764260B (zh) * 2011-04-30 2014-07-30 正大天晴药业集团股份有限公司 一种喜树碱衍生物的药物组合物及其制备方法
WO2013011598A1 (ja) * 2011-07-15 2013-01-24 コニカミノルタホールディングス株式会社 溶解助剤を利用したリポソーム含有製剤およびその製造方法
AU2015369185B2 (en) 2014-12-26 2020-10-22 Nippon Kayaku Kabushiki Kaisha Pharmaceutical preparation of camptothecin-containing polymer derivative
KR20180039628A (ko) 2015-09-03 2018-04-18 니폰 가야꾸 가부시끼가이샤 캄프토테신류 고분자 유도체를 함유하는 의약 조성물
AU2016326747A1 (en) 2015-09-25 2018-03-01 Zy Therapeutics Inc. Drug formulation based on particulates comprising polysaccharide-vitamin conjugate
CN108697806A (zh) * 2016-03-01 2018-10-23 日本化药株式会社 含有喜树碱类高分子衍生物的药物制剂
CN109481691A (zh) * 2018-11-20 2019-03-19 珠海天香苑生物科技发展股份有限公司 吉西他滨-羧甲基多糖共轭物、制备方法及其用途
AU2022396967A1 (en) * 2021-11-26 2024-06-13 Astellas Pharma Inc. Indocyanine compound-containing solid pharmaceutical composition

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5340817A (en) * 1987-04-14 1994-08-23 Research Triangle Institute Method of treating tumors with anti-tumor effective camptothecin compounds
SG50747A1 (en) * 1995-08-02 1998-07-20 Tanabe Seiyaku Co Comptothecin derivatives
TW527183B (en) * 1996-06-06 2003-04-11 Daiichi Seiyaku Co Drug complex
US6288072B1 (en) * 1999-12-29 2001-09-11 Monroe E. Wall Camptothecin β-alanine esters with topoisomerase I inhibition
AR030207A1 (es) * 2000-04-07 2003-08-13 Daiichi Seiyaku Co Composicion farmaceutica que contiene un derivado de camptotecina y procedimiento de preparacion de la misma
AU2001271037A1 (en) * 2000-07-13 2002-01-30 Daiichi Pharmaceutical Co., Ltd. Pharmaceutical compositions containing dds compounds
TWI313609B (en) * 2001-08-21 2009-08-21 Mitsubishi Tanabe Pharma Corp Pharmaceutical composition for inhibiting the metastasis or preventing the recurrence of malignant tumor

Also Published As

Publication number Publication date
MY136696A (en) 2008-11-28
CA2480425A1 (en) 2003-10-23
RU2004133349A (ru) 2005-05-27
AU2003223120A1 (en) 2003-10-27
CN1646172A (zh) 2005-07-27
AR039272A1 (es) 2005-02-16
BR0309283A (pt) 2005-02-15
JP3927954B2 (ja) 2007-06-13
MEP31308A (en) 2010-10-10
RU2315623C2 (ru) 2008-01-27
KR20050000516A (ko) 2005-01-05
US20050215485A1 (en) 2005-09-29
AU2003223120B2 (en) 2006-10-05
PL371677A1 (en) 2005-06-27
EP1501549A2 (en) 2005-02-02
TW200306314A (en) 2003-11-16
ZA200408008B (en) 2005-06-13
KR100700963B1 (ko) 2007-03-28
AU2003223120A2 (en) 2003-10-27
RS91204A (en) 2006-12-15
JP2005523329A (ja) 2005-08-04
WO2003086471A3 (en) 2004-04-15
WO2003086471A2 (en) 2003-10-23
MXPA04010178A (es) 2005-06-08
CN100544769C (zh) 2009-09-30
HRP20040894A2 (en) 2005-10-31
UA77295C2 (en) 2006-11-15

Similar Documents

Publication Publication Date Title
NO20044964L (no) Flytende preparat som omfatter camptothecinderivat og farmasoytisk preparat som kan fremstilles ved a lyofilisere preparatet
EP0513543B1 (de) Amidinophenylalaninderivate, Verfahren zu deren Herstellung, deren Verwendung und diese enthaltende Mittel als Antikoagulantien
EP0781781A3 (en) Camptothecin derivatives
ATE178067T1 (de) Camptothecinderivate
KR910002895A (ko) 펩티딜 아미노디올 레닌 억제제
NO20022264D0 (no) Farmasöytisk blanding inneholdende tolterodin, samt anvendelse derav
JPS62500871A (ja) 薬理活性を有するジペプチド化合物及びそれを含む組成物
WO1996016981A3 (en) Peptide compounds for prevention and/or treatment of no-mediated diseases
HK1160778A1 (en) Pharmaceutical composition comprising an analgesic peptide
NO20000231L (no) Dolastatin-15-derivater
KR102335943B1 (ko) 생물학적 물질 및 미생물의 보존과 보호를 위한 글리코펩티드 유도체
ZA200004680B (en) Certain thiol inhibitors of endothelin-converting enzyme.
EP1485345B1 (de) Hemmstoffe der urokinase, ihre herstellung und verwendung
ES2274106T3 (es) Derivados de pirano como inhibidores tanto de ace como de nep.
WO2001079170A3 (en) Aminophenoxyacetamide derivatives and pharmaceutical composition containing thereof
JP3240580B2 (ja) アスコルビル−ホスホリル−コレステロール
US7521477B2 (en) Vitamin C derivatives with peptide, preparation method thereof and composition comprising the same
ES2427142T3 (es) Inhibidor de la elongación de dendritas para melanocito y preparaciones para la piel para uso externo que lo contiene
EP0292923A3 (en) Piperidine compounds and pharmaceutical uses thereof
KR19990044553A (ko) 펩티드 유도체
JPH0834779A (ja) トコフェロール誘導体
KR101874028B1 (ko) Sac 유도체 또는 smc 유도체를 포함하는 피부 미백용 조성물
CA2379508A1 (en) Biphasic skin composition comprising ascorbic acid, ceramides and betaglycane
RU2219185C2 (ru) Новое полипептидное соединение
MX9603149A (es) Derivados de camptotecina.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application